Bruker Corporation $BRKR Stake Decreased by VELA Investment Management LLC

VELA Investment Management LLC cut its holdings in shares of Bruker Corporation (NASDAQ:BRKR) by 45.0% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 68,000 shares of the medical research company’s stock after selling 55,591 shares during the period. VELA Investment Management LLC’s holdings in Bruker were worth $2,209,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Orbis Allan Gray Ltd acquired a new position in Bruker during the 2nd quarter worth $192,735,000. AQR Capital Management LLC increased its holdings in shares of Bruker by 125.3% during the second quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock valued at $137,065,000 after purchasing an additional 1,850,215 shares during the period. Sculptor Capital LP raised its stake in shares of Bruker by 18.3% during the second quarter. Sculptor Capital LP now owns 3,074,801 shares of the medical research company’s stock valued at $126,682,000 after purchasing an additional 476,363 shares in the last quarter. Brown Advisory Inc. lifted its holdings in Bruker by 13.9% in the second quarter. Brown Advisory Inc. now owns 2,746,163 shares of the medical research company’s stock worth $113,142,000 after purchasing an additional 336,026 shares during the period. Finally, Vaughan Nelson Investment Management L.P. grew its position in Bruker by 61.6% in the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 2,090,155 shares of the medical research company’s stock valued at $67,909,000 after buying an additional 796,510 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Bruker

In related news, VP Mark Munch sold 7,000 shares of the stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $55.00, for a total value of $385,000.00. Following the completion of the sale, the vice president directly owned 128,443 shares of the company’s stock, valued at approximately $7,064,365. This represents a 5.17% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director John A. Ornell sold 6,233 shares of Bruker stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $39.00, for a total value of $243,087.00. Following the transaction, the director directly owned 35,212 shares in the company, valued at approximately $1,373,268. This trade represents a 15.04% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 15,233 shares of company stock worth $726,487 over the last three months. 27.30% of the stock is owned by insiders.

Bruker Price Performance

BRKR stock opened at $51.95 on Thursday. Bruker Corporation has a one year low of $28.53 and a one year high of $61.01. The firm has a 50-day moving average of $47.70 and a two-hundred day moving average of $40.20. The firm has a market capitalization of $7.89 billion, a PE ratio of -324.69, a P/E/G ratio of 6.55 and a beta of 1.17. The company has a current ratio of 1.85, a quick ratio of 0.91 and a debt-to-equity ratio of 0.81.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Monday, November 3rd. The medical research company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.33 by $0.12. Bruker had a negative net margin of 0.61% and a positive return on equity of 15.45%. The business had revenue of $860.50 million during the quarter, compared to the consensus estimate of $847.40 million. During the same quarter in the prior year, the firm earned $0.60 EPS. The firm’s quarterly revenue was down .5% on a year-over-year basis. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. On average, analysts forecast that Bruker Corporation will post 2.69 earnings per share for the current year.

Bruker Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, January 2nd. Stockholders of record on Monday, December 8th were issued a dividend of $0.05 per share. The ex-dividend date was Monday, December 8th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.4%. Bruker’s payout ratio is currently -125.00%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on BRKR. Guggenheim upped their price target on shares of Bruker from $45.00 to $53.00 and gave the stock a “buy” rating in a research note on Monday, January 5th. Rothschild Redb upgraded Bruker to a “strong-buy” rating in a research report on Thursday, November 20th. TD Cowen restated a “hold” rating on shares of Bruker in a report on Wednesday, January 7th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Bruker in a report on Monday, December 29th. Finally, UBS Group boosted their price target on shares of Bruker from $40.00 to $43.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $53.36.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.